Literature DB >> 7670144

Acidic and neutralized metoclopramide formulations sensitize ionizing radiation induced cytotoxicity in a human lung adenocarcinoma xenografted to scid mice.

J Hua1, A Olsson, Y Sheng, R W Pero.   

Abstract

A neutralized formulation (Neu-Sensamide) of metoclopramide (MCA) has been shown to possess reduced sedative side effects compared with the conventional acidic formulations (Primperan). The acidic formulation of MCA has also been shown to sensitize the effect of ionizing radiation (6-8 Gy) using human squamous cell carcinomas from the head and neck xenografted to nude mice. In the present study, 2 mg MCA/kg body weight 1-3 h before treatment with 1 Gy radiation (single dose) was evaluated in scid mice xenografted with a human lung adenocarcinoma. MCA given alone in acidic or neutralized formulations did not show any effect on tumor growth retardation. However, when combined with radiation, both acidic and neutralized formulations of MCA sensitized the cytotoxic effect of radiation directed against the tumors by increasing tumor doubling time, tumor quadrupling time and specific growth delay, and by decreasing area under growth curve measurements. In addition, there was no statistically significant difference between the two formulations of MCA in the efficacy of sensitizing the cytotoxicity of a single low dose (1 Gy) of radiation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7670144     DOI: 10.1097/00001813-199506000-00014

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

1.  CT density in lung cancer patients after radiotherapy sensitized by metoclopramide. A subgroup analysis of a randomized trial.

Authors:  Einar Dale; Vanja Hårsaker; Doris T Kristoffersen; Oyvind Bruland; Dag R Olsen
Journal:  Strahlenther Onkol       Date:  2010-02-22       Impact factor: 3.621

2.  N-substituted benzamides inhibit NFkappaB activation and induce apoptosis by separate mechanisms.

Authors:  D Liberg; B Lazarevic; R W Pero; T Leanderson
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.